Published 1 day ago • loading... • Updated 13 hours ago

Data at Heart Rhythm 2026 highlight key Boston Scientific therapies

On Sunday, Boston Scientific Corporation announced new clinical data for its FARAPULSE PFA Platform and WATCHMAN LAAC devices presented at the Heart Rhythm Society annual meeting in Chicago.
The randomized AVANT GUARD trial met all safety and effectiveness endpoints, demonstrating statistical superiority of the PFA platform over anti-arrhythmic drugs in patients with persistent atrial fibrillation.
Results showed 56.0% effectiveness for PFA at 12 months compared to 30.1% for drug treatment; a CHAMPION-AF sub-analysis confirmed WATCHMAN FLX provided statistically significant bleeding protection.
J.P. Morgan analyst Robbie Marcus noted Sunday that Medtronic remains competitive, as physicians increasingly adopt its technology amid the intensifying $16 billion global electrophysiology market.
Kenneth Stein, M.D., senior vice president at Boston Scientific, said the data "reflect the continued momentum of our cardiovascular portfolio," as the persistent AFib market reaches an estimated $1 billion by 2028.

Insights by Ground AI

19 Articles

4 studies to know from HRS 2026

Boston Scientific, Abbott and Medtronic shared new cardiac device data at the annual Heart Rhythm Society meeting, where market share shifts in pulsed field ablation were on analysts’ minds.

13 hours ago

Read Full Article

WKOW

+16 Reposted by 16 other sources

Center

Data at Heart Rhythm 2026 highlight key Boston Scientific therapies

Positive data for FARAPULSE™ Pulsed Field Ablation and WATCHMAN™ LAAC Devices underscore therapy safety and effectiveness in late-breaking clinical trial sessions

1 day ago

Read Full Article